ClinicalTrials.gg
RecruitingNCT05590130Oxygap pongUpdated Nov 5, 2026

Comparison of Two Oxygenation Targets With Two Different Oximeters - Impact on Oxygen Flow Rates and Oxygenation

An interventional study of Manual Oxygen titration with Philips oximeter (SpO2 target 90%) and Manual oxygen titration with Nonin oximeter (SpO2 target 90%) in Oxygen Toxicity and Respiratory Failure, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Laval University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.

Planned enrollment
30th of 66
40 · median 31
Started
2022
with 5 others
No phase
46 of 94
10 open now
Primary completion
2027-06
later than 21 of 28 live
Registered
78th of 94
by date
Lead sponsor
8 of 94
Laval University

Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 30th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2022, is one of 46 with no phase, reaches primary completion later than 21 of the 28 other live ones, and was the 78th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Respiratory Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

The investigators recently evaluated 4 different oximeters among the most commonly used with arterial catheter in place and compared SpO2 with SaO2 obtained on arterial gas. Correlations between SaO2 and SpO2 were poor for all oximeters, as previously known, and SpO2-SaO2 bias were different between oximeters. Some oximeters (Masimo, Nellcor) had lower biases but they detected less well hypoxemia. Some oximeters underestimated SaO2 (Nonin) but detected very well hypoxemia, and some overestimated SaO2 (Philips). The investigators concluded that oximeters provide different informations to clinicians, and oxygenation targets should take into account for these differences.

The assumption is that the SpO2 target AND oximeter used will both have an impact on oxygen flows and that these effects will add up. With a high SpO2 target, oxygen flows will be significantly greater and with the Nonin oximeter, the required flows will be greater than with the Philips oximeter.

NB: the results obtained were in a population with light skin pigmentation (96% of the patients were Fitzpatrick 1-2, reflecting the local hospitalized population).

Read the detailed description

The oximeters to be evaluated will be the Nonin (Plymouth, MN), and the Philips (Eindhoven, Netherlands). The sensors used will be digital reusable sensors for all oximeters. Because of the impact of the fingers used for SpO2 measurement, each oximeter will be randomly assigned a different finger to each patient (digit 2 and 3 on the hand opposite to the arterial catheter).

Two SpO2 targets will be assessed: 90% and 94%. A total of four 10-minute periods will be performed in randomized order: Nonin 90, Nonin 94, Philips 90, and Philips 94.

At the end of each 10-minute period, arterial gas will be collected through the arterial catheter.

The adjustment of the oxygen flow rates will be performed manually. The average oxygen flow of the last 2 minutes of the period will be considered.

03

Conditions studied

  • Oxygen Toxicity
  • Respiratory Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age
  • Patients admitted to postoperative cardiac surgery intensive care unit
  • Presence of an arterial catheter Specific for the extubate patient
  • Ongoing on conventional oxygen therapy at moderate flow (up to a maximum of 5L/min) with SpO2 between 88 and 100% with the usual oximeter and nasal cannula.
  • SpO2 \< 92% ambient air Specific for the intubate patient FiO2 \<= 0.60 with SpO2 between 88 and 100% with usual oximeter SpO2 \< 92% with FiO2 0.21

Exclusion criteria

Exclusion Criteria:

  • No SpO2 signal with oximeter in use
  • False nails or nail polish
  • Methemoglobinemia >0.015 on last available arterial gas
  • Patient in isolation (multi-resistant bacteria, C-Difficile, SARS-CoV-2 ...) Specific for the extubate patient
  • Expected to use another respiratory support within one hour of inclusion (NIV or nasal high flow oxygen) Planned extubation within one hour of inclusion
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Nonin oximeter with a 90% SpO2 target

    During this periods , oxygen will be administered in an manual titration with the FreeO2 device (fixed flow mode) to reach 90% of SpO2.

    Device: Manual oxygen titration with Nonin oximeter (SpO2 target 90%)

  • Experimental
    Philips oximeter with a 90% SpO2 target

    During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 90% of SpO2.

    Device: Manual Oxygen titration with Philips oximeter (SpO2 target 90%)

  • Experimental
    Nonin oximeter with a 94% SpO2 target

    During this periods , oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode) to reach 94% of SpO2.

    Device: Manual oxygen titration with Nonin oximeter (SpO2 target 94%)

  • Experimental
    Philips oximeter with a 94% SpO2 target

    During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 94% of SpO2.

    Device: Manual Oxygen titration with Philips oximeter (SpO2 target 94%)

Interventions

  • DeviceManual Oxygen titration with Philips oximeter (SpO2 target 90%)

    Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter

  • DeviceManual oxygen titration with Nonin oximeter (SpO2 target 90%)

    Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter

  • DeviceManual Oxygen titration with Philips oximeter (SpO2 target 94%)

    Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter

  • DeviceManual oxygen titration with Nonin oximeter (SpO2 target 94%)

    Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter

06

What researchers measure

Primary outcomes

  1. Oxygen flow (or FiO2)

    Oxygen flows (or FiO2) at the end of each study period (last minute average) to reach SpO2 target to reach SpO2 target with specific oximeter

    Time frame: Mean Oxygen flow in the two last minute of each study period (between minute 8 and 10)

Secondary outcomes

  1. Difference between SpO2 and SaO2

    Difference (%) between SpO2 from each oximeter and SaO2 (% of SaO2 overestimation and underestimation for each oximeter)

    Time frame: assessed up to 10 minutes - at the same of the arterial blood gases punction

Other outcomes

  1. Mean difference on oxymeter

    Mean (±SD) of the gaps between the different oximeters tested

    Time frame: assessed up to 10 minutes - at the same of the arterial blood gases punction

  2. Occult hypoxemia

    Percentage of occult hypoxemia (SaO2\<90% and SpO2\>=90%)

    Time frame: assessed up to 10 minutes - at the same of the arterial blood gases punction

  3. Occult hyperoxemia

    Perrcentage of occult hyperoxemia (SaO2\>96% and SpO2\<=96%)

    Time frame: assessed up to 10 minutes - at the same of the arterial blood gases punction

  4. Partial oxygen weaning

    Rate of partial oxygen weaning (Oxygen flow \<=0.5 L/min)

    Time frame: Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)

  5. Complete oxygen weaning

    Rate of complete oxygen weaning (Oxygen flow =0 L/min or FiO2 0.21)

    Time frame: Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)

  6. Respiratory support escalation

    Indication of initiation of respiratory support escalation (Oxygen flow \>6 L/min or FiO2 \> 0.60)

    Time frame: Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jun 2027, 55 months after the start.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 55 months is above that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Jun 2027 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 21, 2022
StartActual
Nov 16, 2022
Primary completionEst.
Jun 2027was Dec 2026
CompletionEst.
Dec 2027was Jun 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Jun 2027
Nov 5, 2026
Study completion
Jun 2027→Dec 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 2026→Jun 2027
    Study completion Jun 2027→Dec 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05590130
Lead sponsor
Laval University
Responsible party
François Lellouche (Principal investigator, Laval University) — Principal investigator
First posted
Oct 21, 2022
Start date
Nov 16, 2022
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Francois Lellouche
Contact
francois.lellouche@criucpq.ulaval.ca
418656-8711 ext. 3572
Pierre Alexandre Bouchard
Contact
pierre-alexandre.bouchard@criucpq.ulaval.ca
418656-8711 ext. 2712

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion